From the Departments of Neurology (E.A.M., M.S.) and
Neurosurgery (A.M.M., R.C., M. Fusco), and.
AJNR Am J Neuroradiol. 2020 Apr;41(4):639-644. doi: 10.3174/ajnr.A6478. Epub 2020 Mar 12.
The increased severity of white matter disease is associated with worse outcomes and an increased rate of intracerebral hemorrhage in patients with ischemic stroke undergoing thrombolytic treatment. However, whether white matter disease is associated with outcomes in patients undergoing endovascular treatment remains unclear.
In this prespecified exploratory analysis of our prospective multi-institutional study that enrolled consecutive adult patients with anterior circulation ischemic stroke undergoing endovascular treatment from November 2017 to September 2018, we compared the following outcomes between patients with none-to-minimal (van Swieten score, 0-2) and moderate-to-severe (van Swieten score, 3-4) white matter disease using logistic regression: 90-day mRS 3-6, death, intracerebral hemorrhage, successful recanalization, and early neurologic recovery.
Of the 485 patients enrolled in the Blood Pressure after Endovascular Stroke Therapy (BEST) study, 389 had white matter disease graded (50% women; median age, 68 years; range, 58-79 years). A van Swieten score of 3-4 ( = 74/389, 19%) was associated with a higher rate of 90-day mRS of 3-6 (45% versus 18%; adjusted OR, 2.73; 95% CI, 1.34-5.93; = .008). Although the death rate was higher in patients with van Swieten scores of 3-4 (26% versus 15%), the adjusted likelihood was not significantly different (adjusted OR, 1.14; 95% CI, 0.56-2.26; = .710). Ordered regression revealed a shift toward worse mRS scores with increasing van Swieten scores (adjusted common OR, 3.04; 95% CI, 1.93-4.84; < .001). No associations between white matter disease severity and intracerebral hemorrhage, successful recanalization, and early neurologic recovery were observed.
Moderate-to-severe white matter disease is associated with worse outcomes in patients undergoing endovascular treatment without a significant increase in hemorrhagic complications. Studies comparing patients with and without endovascular treatment are necessary to determine whether the benefit of endovascular treatment is attenuated with greater white matter disease.
在接受溶栓治疗的缺血性脑卒中患者中,白质病变严重程度增加与预后较差和脑出血发生率增加相关。然而,血管内治疗患者的白质病变是否与预后相关尚不清楚。
本研究为前瞻性多中心研究的预设探索性分析,纳入 2017 年 11 月至 2018 年 9 月接受血管内治疗的前循环缺血性脑卒中成年连续患者,使用逻辑回归比较白质病变程度为无至轻度(van Swieten 评分 0-2)和中至重度(van Swieten 评分 3-4)患者的以下结局:90 天 mRS3-6、死亡、脑出血、血管再通成功和早期神经功能恢复。
在 BEST 研究中,共纳入 485 例患者,其中 389 例患者的白质病变程度可评估(50%为女性;中位年龄 68 岁;范围 58-79 岁)。van Swieten 评分 3-4( = 74/389,19%)与 90 天 mRS 为 3-6 的发生率较高相关(45%比 18%;校正 OR,2.73;95%CI,1.34-5.93; =.008)。尽管 van Swieten 评分 3-4 患者的死亡率较高(26%比 15%),但校正后差异无统计学意义(校正 OR,1.14;95%CI,0.56-2.26; =.710)。有序回归显示,随着 van Swieten 评分的增加,mRS 评分趋于恶化(校正后常见 OR,3.04;95%CI,1.93-4.84; < .001)。白质病变严重程度与脑出血、血管再通成功和早期神经功能恢复之间无相关性。
血管内治疗患者中,中至重度白质病变与预后较差相关,且不会显著增加出血性并发症。有必要开展比较血管内治疗与非血管内治疗患者的研究,以确定白质病变加重是否会削弱血管内治疗的获益。